Literature DB >> 11866262

The adoption of ablation therapy for Barrett's esophagus: a cohort study of gastroenterologists.

Cary P Gross1, Marcia Cruz-Correa, Marcia Irene Canto, Corlina McNeil-Solis, Thomas W Valente, Neil R Powe.   

Abstract

OBJECTIVES: Although ablation therapy may be useful in the treatment of Barrett's esophagus. evidence of effectiveness is scarce, and little is known about current utilization of ablation. We aimed to determine whether the use of ablation was increasing in a cohort of gastroenterologists, and to identify physician beliefs and characteristics associated with ablation use.
METHODS: We surveyed a national sample of gastroenterologists about ablation use, with an 18-month follow-up. The self-administered instrument included questions about demographic characteristics, attitudes about ablation therapy, and prior experience with ablation. Case scenarios were also included. We used logistic regression to identify factors associated with the use of ablation in patients with Barrett's esophagus.
RESULTS: Two hundred seventy-nine (50.3% of those eligible) responded to the baseline survey. Few agreed that ablation lowers the risk of adenocarcinoma (15%) or is supported by the medical literature (19%). However, 25% of respondents reportedly had used ablation at baseline, and this increased to 36% in the follow-up survey (p = 0.0003). The use of ablation was significantly associated with physician age greater than 54 yr (odds ratio [OR] = 2.77, 95% CI = 1.04-7.37) and the belief that ablation was used by colleagues (OR = 13.27, 95% CI = 4.44-39.64) or decreases medical costs (OR = 5.07, 95% CI = 1.00-25.74).
CONCLUSIONS: Although few gastroenterologists agreed that ablation is effective, a significant proportion had adopted its use. There was a significant increase in ablation use during our study period, and the characteristic that was most strongly associated with ablation use was the belief that colleagues used it.

Entities:  

Mesh:

Year:  2002        PMID: 11866262     DOI: 10.1111/j.1572-0241.2002.05455.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus.

Authors:  Katerina Dvorak; Lois Ramsey; Claire M Payne; Richard Sampliner; Ronnie Fass; Harris Bernstein; Anil Prasad; Harinder Garewal
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

3.  Using sociometric measures to assess nonresponse bias.

Authors:  Britt Livak; John A Schneider
Journal:  Ann Epidemiol       Date:  2014-04-24       Impact factor: 3.797

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.